Here's the honest answer: VIP isn't a common-objective anti-inflammatory peptide you'll be able to substitute into any protocol anticipating broad immune suppression. Its effects are receptor-specific, tissue-dependent, and timing-sensitive in ways in which make protocol design considerably much more advanced than simply just dosing and measuring c